Please use this identifier to cite or link to this item:
Title: Metformin hydrochloride delayed release tablets – a comparative dissolution profiles study
Authors: Bogantes-Molina, Joselyn
Madrigal-Redondo, German
Berrocal-Barrantes, Lorena
Chavarría-Rojas, Marianela
Acuña-Amador, Daniel Alejandro
Vargas-Zúñiga, Rolando
Keywords: metformin hydrochloride
dissolution profiles
multisource drugs
Publisher: GSC Biological and Pharmaceutical Sciences
Citation: Bogantes-Molina, J., Madrigal-Redondo, G., Berrocal-Barrantes, L., Chavarría-Rojas, M., Acuña-Amador, D. A., y Vargas-Zúñiga, R. (2019). Metformin hydrochloride delayed release tablets – a comparative dissolution profiles study. GSC Biological and Pharmaceutical Sciences, 8(2), 113-118.
Abstract: Multisource or generic drugs represent an important decrease in treatment cost for multiple diseases, which improves patient’s medicine access. However, the therapeutic equivalence between original drugs (innovator) and generic or multisource drugs need to be demonstrated. Bioequivalence represents drug efficacy and higher security for patients, and it is considered as a fundamental factor for product commercialization. This work main objective was to make a comparison between the dissolution profiles of the original and multisource metformin hydrochloride tablets commercialized in Costa Rica. We used a validated analytical method to quantify metformin in dissolution medium, a phosphates buffered solution of pH (6.8 ± 0.05). The obtained results demonstrated products interchangeability using the model-independent similarity factor (f2) and difference factor (f1) criteria.
Appears in Collections:Artículos publicados en revistas internacionales

Files in This Item:
There are no files associated with this item.

This item is licensed under a Creative Commons License Creative Commons